What was studied?
An ongoing randomized, double-blind, placebo-controlled trial enrolled people with biopsy-defined MASH and stage F2 or F3 fibrosis. This publication reported a planned analysis of the first 800 participants at week 72, within a longer study.
What did the researchers report?
Semaglutide improved the reported histologic endpoints, including resolution of steatohepatitis without worsening fibrosis and improvement in fibrosis without worsening steatohepatitis. These outcomes describe the liver-biopsy assessment at the analyzed time point.
What are the limits?
An interim histology result does not alone establish long-term prevention of liver failure, transplantation or death. The population had specified disease and fibrosis stages. The findings relate to the pharmaceutical trial product and should not be used as catalog-material efficacy claims.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.